Should you sell Merck & Co., Inc. or reduce the position?
Calculate what you would remove, what you would retain, and which assumptions support continuing to own it.
Price as of Oct 17, 2026, 10:01 PM UTC (polygon last daily bar) · Evidence through Oct 1, 2026
What has changed in the case for owning it?
Market Ontology's model values Merck & Co., Inc. at $102.23 per share against $145.95 (-30.0%). 4 dated developments in the last 45 days reach the position.
| Development | Evidence | Assumption affected | Consequence for the case |
|---|---|---|---|
| Oct 1, 2026 · Merck declines 2.66% ahead of October 29 Q3 earnings as consensus models 12.8% EPS drop | 1 source | net margin contraction via higher operational R&D spending | Weakens the case for owning |
| Oct 1, 2026 · Merck Faces 12.8% EPS Contraction Forecast Ahead of October 29 Print | 1 source | quarterly earnings multiple compression on projected 12.79% EPS drop | Mixed |
| Oct 1, 2026 · Merck Sets Q3 2026 Earnings Release for October 29 Amid Pipeline Scrutiny | 1 source | oncology product sales trajectory and R&D pipeline replacement | Mixed |
| Sep 16, 2026 · Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy | 1 source | combination regimen pipeline expansion in immuno-oncology | Supports the case for owning |
What changes if you sell?
| Keep current position | Sell selected quantity | Exit position | |
|---|---|---|---|
| Shares remaining | 100 | 50 | 0 |
| Estimated proceeds after included transaction costs | — | $7,294 | $14,588 |
| Downside case ($64.97) outcome | −$8,098 | −$4,049 | $0 |
| Upside case ($168.62) outcome | $2,267 | $1,134 | $0 |
| Remaining exposure | $14,595 | $7,298 | $0 |
Included costs: an assumed 5 bps for commission and spread. Tax treatment: not calculated; cost basis is not used in this comparison.
Undecided: sale proceeds and remaining exposure are calculated; replacement performance is left unresolved.
What would justify keeping the remaining position?
- Revenue growth (yr 1) holds near -8.84%: Trailing 4-year revenue CAGR of -8.8%, faded toward terminal growth over 5 years.
- Operating margin (steady-state) holds near 15%: Anchored to mean operating margin of 15.0% across the last 0 reported periods.
- Discount rate (WACC) holds near 6.1%: CAPM baseline: 5.10% risk-free + β0.13 × 5.5% ERP = 5.83%.
What would justify investigating it again after an exit?
- Implied revenue growth (next yr → terminal) moves relative to 5.74%: Growth rate that reconciles the current share price to a 5y DCF holding margin, WACC and terminal g fixed.
- Implied steady-state FCF margin moves relative to 35.98%: FCF margin the market needs to justify the current price at modeled growth and WACC.
- The price falls below the downside value of $64.97.
Preserve the reasoning behind the sale.
Save the reduction you're considering, the evidence behind it, and your conditions for reviewing the remaining position. If you exit, keep the research and specify what would justify revisiting MRK.
Should I buy?Should I hold?Should I hedge?How to hedgeImpact ledger